MEB Stock Chart & Stats
€23.72
€0.50(2.03%)
At close: 4:00 PM EDT
€23.72
€0.50(2.03%)
Day’s Range― - ―
52-Week Range€19.49 - €37.82
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€948.13M
Enterprise Value€731.65M
Total Cash (Recent Filing)€84.82M
Total Debt (Recent Filing)€57.41M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Dec 09, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,929,110
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.86Price Target Upside34.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€37.99M
Bulls Say, Bears Say
Bulls Say
Recurring Royalty GrowthThe rising royalty share indicates a durable shift toward recurring, asset-light revenue rather than reliance on one-time milestones. Strong UZEDY sales growth and Teva’s potential $300M 2026 sales outlook could improve revenue quality and support future operating leverage.
Olanzapine Regulatory ProgressFDA acceptance and European filing materially advance a second potential royalty engine beyond UZEDY. If approval and launch remain on schedule, olanzapine could diversify revenue, broaden the commercial platform, and provide meaningful royalties from 2027.
Expanding Partnered PipelineA broad internal and partner-funded pipeline increases the number of opportunities that can validate BEPO and generate future milestones or royalties. Advancing the AbbVie collaboration toward clinical testing also supports platform credibility and longer-term portfolio depth.
Bears Say
Persistent Losses And Cash BurnSustained losses and renewed cash consumption show that commercial progress has not yet translated into self-funded operations. Continued investment may accelerate the pipeline, but it also increases reliance on liquidity, future monetization, or additional funding.
Revenue Volatility From MilestonesDependence on milestone receipts makes reported revenue uneven and reduces visibility into underlying growth from period to period. Although recurring royalties are improving, absent deal payments can still materially affect results while the company scales its commercial base.
Partner And Regulatory Execution RiskMedinCell’s development and commercialization model relies substantially on partners to execute sales, approvals, and clinical plans. Delays, conservative guidance, or changed regulatory pathways could postpone royalties and weaken the timing of expected pipeline value.
MedinCell SA News
MEB FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €19.49 and its highest was €37.82 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €948.13M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 09, 2026 which is in 39 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -€0.45 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.11.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,929,110 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.45 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went down -0.443%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in DE:MEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MEB Stock 12 Month Forecast
Average Price Target
€31.86
▲(34.34% Upside)